Published in J Infect Dis on February 01, 1978
The Mycobacterium avium complex. Clin Microbiol Rev (1993) 7.67
Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother (1982) 3.84
LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity. Antimicrob Agents Chemother (1979) 3.49
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother (1982) 2.28
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother (2000) 2.27
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med (2014) 1.96
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother (1989) 1.89
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2004) 1.72
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol (1992) 1.53
Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (2002) 1.53
Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother (1988) 1.52
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother (1986) 1.51
Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother (1993) 1.50
Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1979) 1.47
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother (2006) 1.46
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother (2006) 1.46
Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One (2010) 1.45
Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J Cell Biol (1999) 1.44
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother (2003) 1.44
Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob Agents Chemother (2007) 1.37
Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon. Infect Immun (1981) 1.35
In vitro activity of ciprofloxacin against aerobic gram-negative bacteria. Antimicrob Agents Chemother (1984) 1.29
Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrob Agents Chemother (1998) 1.26
Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol (2005) 1.25
In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother (1995) 1.24
Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother (2011) 1.24
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (2006) 1.23
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother (1997) 1.23
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother (2002) 1.23
In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother (2004) 1.21
In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother (1995) 1.21
Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob Agents Chemother (2006) 1.21
Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics. Antimicrob Agents Chemother (1978) 1.20
Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother (1993) 1.20
In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol (2007) 1.20
Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening. Eukaryot Cell (2004) 1.19
Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother (1987) 1.19
In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother (1990) 1.19
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob Agents Chemother (2008) 1.18
Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. Antimicrob Agents Chemother (2003) 1.17
In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother (1999) 1.16
Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (1997) 1.16
Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides. Antimicrob Agents Chemother (1980) 1.13
Comparison of cefotaxime, imipenem-cilastatin, ampicillin-gentamicin, and ampicillin-chloramphenicol in the treatment of experimental Escherichia coli bacteremia and meningitis. Antimicrob Agents Chemother (1985) 1.13
Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother (2009) 1.12
Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax (1987) 1.12
Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Antimicrob Agents Chemother (1992) 1.09
Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob Agents Chemother (1994) 1.09
In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother (2007) 1.09
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay. Antimicrob Agents Chemother (2009) 1.08
Paradox between the responses of Escherichia coli K1 to ampicillin and chloramphenicol in vitro and in vivo. Antimicrob Agents Chemother (1984) 1.08
Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect (2015) 1.08
In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob Agents Chemother (1999) 1.07
Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia (2009) 1.06
Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother (2002) 1.04
In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother (2002) 1.04
In vitro activity and interaction of clindamycin combined with dihydroartemisinin against Plasmodium falciparum. Antimicrob Agents Chemother (2003) 1.03
Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum. Antimicrob Agents Chemother (1999) 1.03
Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother (1998) 1.02
Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther (2013) 1.02
In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations. Antimicrob Agents Chemother (1993) 1.02
Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents Chemother (2006) 1.02
In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes. Antimicrob Agents Chemother (1982) 1.01
Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol Res (2008) 1.00
Inhibitory effects of chlorpromazine on Candida species. Antimicrob Agents Chemother (1985) 1.00
Anti-plasmodial polyvalent interactions in Artemisia annua L. aqueous extract--possible synergistic and resistance mechanisms. PLoS One (2013) 1.00
Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. Antimicrob Agents Chemother (1989) 0.99
In vitro susceptibilities of Actinobacillus actinomycetemcomitans to a number of antimicrobial combinations. Antimicrob Agents Chemother (1992) 0.98
Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother (1995) 0.98
Oleic acid biosynthesis in Plasmodium falciparum: characterization of the stearoyl-CoA desaturase and investigation as a potential therapeutic target. PLoS One (2009) 0.98
Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob Agents Chemother (1984) 0.98
Cefotaxime stability during in vitro microbiological testing. Antimicrob Agents Chemother (1987) 0.97
Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother (2006) 0.96
In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Antimicrob Agents Chemother (2006) 0.96
Biguanide-atovaquone synergy against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (2002) 0.96
Pharmacokinetics and bacteriological efficacy of mezlocillin in experimental Escherichia coli and Listeria monocytogenes meningitis. Antimicrob Agents Chemother (1984) 0.96
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog (2008) 0.95
Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin. PLoS Pathog (2013) 0.95
In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2006) 0.95
Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases. Antimicrob Agents Chemother (2007) 0.95
Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob Agents Chemother (2006) 0.94
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 0.94
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle (2011) 0.94
Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother (2012) 0.94
Synergistic effects between amoxicillin, metronidazole, and the hydroxymetabolite of metronidazole against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother (1991) 0.93
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med (2015) 0.93
Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol (2015) 0.93
Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth. Antimicrob Agents Chemother (1989) 0.93
Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery? J Med Chem (2015) 0.93
The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol (2006) 0.92
Gametocytocidal activity and synergistic interactions of riboflavin with standard antimalarial drugs against growth of Plasmodium falciparum in vitro. Antimicrob Agents Chemother (2000) 0.90
Rifampin, ampicillin, streptomycin, and their combinations in the treatment of enterococcal pyelonephritis in rats. Antimicrob Agents Chemother (1981) 0.90
Morphological expressions of antibiotic synergism against Pseudomonas aeruginosa as observed by scanning electron microscopy. Antimicrob Agents Chemother (1980) 0.90
In vitro synergistic effect of fluoroquinolone analogues in combination with artemisinin against Plasmodium falciparum; their antiplasmodial action in rodent malaria model. Malar J (2015) 0.89
Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol (1971) 3.47
Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol (1977) 2.89
Postoperative depression of the lymphocyte response to phytohaemagglutinin. Lancet (1967) 2.57
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06
In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer (1982) 1.82
Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55
Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53
Time-dependent immunosuppressive effects of anti-thymocyte serum. Nature (1967) 1.48
meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47
Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44
Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer (1991) 1.42
Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res (1974) 1.36
Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29
Correlations between methods for measurement of synergy. J Infect Dis (1980) 1.29
The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26
Cell respiration as a requirement for antibody release in vitro. Nature (1968) 1.21
Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19
Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol (1976) 1.11
The therapeutic significance of the dose response curve for antilymphocytic serum. Transplantation (1971) 1.02
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Immunosuppression by L-asparaginase. Nature (1970) 0.99
The relation between the physico-chemical properties and immunosuppressive effects of an homologous series of sulphonic acid esters. Immunology (1967) 0.97
The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer (1971) 0.95
Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother (1983) 0.95
Effects of L-asparaginase on lymphocyte-target cell reactions in vitro. Nature (1970) 0.95
Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94
Immunosuppressive agents: the design of selective therapeutic schedules. Antibiot Chemother (1969) 0.93
The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx. Acta Otolaryngol (1989) 0.91
Synergy assessment with growth curves. J Infect Dis (1984) 0.90
Radiosensitivity of immunologically activated cells. Nature (1966) 0.89
Minor synergy and antagonism may be clinically important. J Antimicrob Chemother (1987) 0.88
Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation (1975) 0.87
HPD - a study of its components and their properties. Adv Exp Med Biol (1983) 0.87
The localization of haemolytic antibody in sections of lymphoid organs: an improved method. Immunology (1970) 0.84
Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemother (1988) 0.84
Role of mitosis and mitotic inhibition in the immunosuppressive action of thioguanine. Nature (1966) 0.83
Consequences of synergy between environmental carcinogens. Environ Res (1985) 0.82
Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobilization Biotechnol (1992) 0.82
Time-dependence and selectivity of immunosuppressive agents. Immunology (1979) 0.82
The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82
Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation (1965) 0.81
Effect of some metabolic inhibitors on plaque formation in Jerne plates. Nature (1967) 0.81
Transplantation and immunosuppression. Mod Trends Immunol (1967) 0.81
Differential asparaginase sensitivity of T-cell and B-cell responses. Clin Exp Immunol (1973) 0.80
The mode of action of cytotoxic drugs. Proc R Soc Med (1970) 0.80
Porphyrin sensitizers in tumour phototherapy. Novel sensitizers of the chlorin and bacteriochlorin class with amphiphilic properties. J Photochem Photobiol B (1990) 0.79
Research ethics and deception. Lancet (1980) 0.78
Letter: Predicting response of human cancer to chemotherapy. Lancet (1974) 0.78
Immunosuppressive agents: generation and consequences of differing dose-response curves. Proc R Soc Med (1972) 0.78
Immunosuppression by platinum diamines. Br J Cancer (1971) 0.77
Neutrophil function during chemotherapy for Hodgkin's disease. Br J Cancer (1981) 0.77
Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. Br J Cancer (1991) 0.77
Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts. Immunology (1976) 0.77
Concepts for describing the interaction of two agents. Radiat Res (1991) 0.75
Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes. Br J Cancer (1982) 0.75
Autoimmunity and immunosuppression. Proc R Soc Med (1967) 0.75
Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy. Br J Cancer (1969) 0.75
Modes of action of immunosuppressive agents. Proc R Soc Med (1967) 0.75
Effect of L-asparaginase on germinal centre haemolysin. Nature (1971) 0.75
Intrathecal interferon, indomethacin, and multiple sclerosis. Lancet (1987) 0.75
Antagonism between radiosensitizing agents. Br J Radiol (1988) 0.75
The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil. Chemotherapy (1979) 0.75
Anti-HIV synergy between dextran sulphate and zidovudine. Lancet (1987) 0.75
Muscle damage and recovery in the rabbit tongue following photodynamic therapy with haematoporphyrin derivative. Acta Otolaryngol (1991) 0.75
Growth of human and rat tumours in immunosuppressed mice. J Pathol (1972) 0.75
Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects. Br J Urol (1979) 0.75
The last surviving cancer cell: the chances of killing it. Cancer Chemother Rep (1968) 0.75